WallStreetZenWallStreetZen

NASDAQ: VTRS
Viatris Inc Stock

$11.24+0.05 (+0.45%)
Updated Jul 12, 2024
VTRS Price
$11.24
Fair Value Price
N/A
Market Cap
$13.38B
52 Week Low
$8.74
52 Week High
$13.62
P/E
-374.67x
P/B
0.67x
P/S
0.93x
PEG
N/A
Dividend Yield
2.14%
Revenue
$15.36B
Earnings
-$56.10M
Gross Margin
41.7%
Operating Margin
4.23%
Profit Margin
-0.4%
Debt to Equity
1.37
Operating Cash Flow
$2B
Beta
0.78
Next Earnings
Aug 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A

VTRS Overview

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VTRS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VTRS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VTRS is good value based on its book value relative to its share price (0.67x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.27x)
P/B vs Industry Valuation
VTRS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more VTRS due diligence checks available for Premium users.

Be the first to know about important VTRS news, forecast changes, insider trades & much more!

VTRS News

Valuation

VTRS fair value

Fair Value of VTRS stock based on Discounted Cash Flow (DCF)
Price
$11.24
Fair Value
$31.11
Undervalued by
63.87%
VTRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VTRS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-374.67x
Industry
-1.24x
Market
32.2x

VTRS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.67x
Industry
2.27x
VTRS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VTRS's financial health

Profit margin

Revenue
$3.7B
Net Income
$113.9M
Profit Margin
3.1%
VTRS's Earnings (EBIT) of $649.30M... subscribe to Premium to read more.
Interest Coverage Financials
VTRS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$47.3B
Liabilities
$27.3B
Debt to equity
1.37
VTRS's short-term assets ($12.92B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VTRS's long-term liabilities ($19.57B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VTRS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VTRS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$614.6M
Investing
-$154.3M
Financing
-$425.6M
VTRS's operating cash flow ($2.44B)... subscribe to Premium to read more.
Debt Coverage Financials

VTRS vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
VTRS$13.38B+0.45%-374.67x0.67x
RDY$13.28B+1.08%19.82x3.94x
NBIX$14.84B+0.63%39.10x6.22x
CTLT$10.42B-0.84%-8.87x2.89x
LNTH$8.55B-0.16%18.31x9.05x

Viatris Stock FAQ

What is Viatris's quote symbol?

(NASDAQ: VTRS) Viatris trades on the NASDAQ under the ticker symbol VTRS. Viatris stock quotes can also be displayed as NASDAQ: VTRS.

If you're new to stock investing, here's how to buy Viatris stock.

What is the 52 week high and low for Viatris (NASDAQ: VTRS)?

(NASDAQ: VTRS) Viatris's 52-week high was $13.62, and its 52-week low was $8.74. It is currently -17.46% from its 52-week high and 28.6% from its 52-week low.

How much is Viatris stock worth today?

(NASDAQ: VTRS) Viatris currently has 1,190,675,819 outstanding shares. With Viatris stock trading at $11.24 per share, the total value of Viatris stock (market capitalization) is $13.38B.

Viatris stock was originally listed at a price of $9.31 in Dec 31, 1997. If you had invested in Viatris stock at $9.31, your return over the last 26 years would have been 20.77%, for an annualized return of 0.73% (not including any dividends or dividend reinvestments).

How much is Viatris's stock price per share?

(NASDAQ: VTRS) Viatris stock price per share is $11.24 today (as of Jul 12, 2024).

What is Viatris's Market Cap?

(NASDAQ: VTRS) Viatris's market cap is $13.38B, as of Jul 15, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Viatris's market cap is calculated by multiplying VTRS's current stock price of $11.24 by VTRS's total outstanding shares of 1,190,675,819.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.